Merck (MRK) Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in Patients With High-Risk Early-Stage TNBC
Go back to Merck (MRK) Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in Patients With High-Risk Early-Stage TNBC| Merck & Co. (NYSE: MRK) | Delayed: 127.00 +0.12 (0.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.88 | 52 Week High | $65.46 | |||
| Open | $126.82 | 52 Week Low | $47.97 | |||
| Day High | $127.59 | P/E | 86.39 | |||
| Day Low | $125.35 | EPS | $1.47 | |||
| Volume | 7,085,231 | |||||
